The latest price target for Aclaris Therapeutics (NASDAQ:ACRS) was reported by LifeSci Capital on June 2, 2026. The analyst firm set a price target for $13.00 expecting ACRS to rise to within 12 months (a possible 189.53% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Aclaris Therapeutics (NASDAQ:ACRS) was provided by LifeSci Capital, and Aclaris Therapeutics initiated their outperform rating.

The last upgrade for Aclaris Therapeutics Inc happened on December 23, 2024 when HC Wainwright & Co. raised their price target to $20. HC Wainwright & Co. previously had a neutral for Aclaris Therapeutics Inc.

The last downgrade for Aclaris Therapeutics Inc happened on January 22, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Aclaris Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on June 2, 2026 so you should expect the next rating to be made available sometime around June 2, 2027.

While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a initiated with a price target of $0.00 to $13.00. The current price Aclaris Therapeutics (ACRS) is trading at is $4.49, which is within the analyst’s predicted range.